Institution
Tata Memorial Hospital
Healthcare•Mumbai, India•
About: Tata Memorial Hospital is a healthcare organization based out in Mumbai, India. It is known for research contribution in the topics: Cancer & Breast cancer. The organization has 3187 authors who have published 4636 publications receiving 109143 citations.
Topics: Cancer, Breast cancer, Population, Radiation therapy, Carcinoma
Papers published on a yearly basis
Papers
More filters
••
Peter MacCallum Cancer Centre1, Garvan Institute of Medical Research2, University of Melbourne3, Tata Memorial Hospital4, Huntsman Cancer Institute5, Mount Sinai Hospital6, Oslo University Hospital7, Gachon University8, Asan Medical Center9, The Royal Marsden NHS Foundation Trust10, University College Hospital11, Commonwealth Scientific and Industrial Research Organisation12
TL;DR: The genetic basis for bone and soft-tissue sarcoma seen in routine clinical practice is investigated and several classes of pathogenic variants (known, expected, or predicted) were associated with earlier age of cancer onset.
Abstract: Summary Background Sarcomas are rare, phenotypically heterogeneous cancers that disproportionately affect the young. Outside rare syndromes, the nature, extent, and clinical significance of their genetic origins are not known. We aimed to investigate the genetic basis for bone and soft-tissue sarcoma seen in routine clinical practice. Methods In this genetic study, we included 1162 patients with sarcoma from four cohorts (the International Sarcoma Kindred Study [ISKS], 966 probands; Project GENESIS, 48 probands; Asan Bio-Resource Center, 138 probands; and kConFab, ten probands), who were older than 15 years at the time of consent and had a histologically confirmed diagnosis of sarcoma, recruited from specialist sarcoma clinics without regard to family history. Detailed clinical, pathological, and pedigree information was collected, and cancer diagnoses in probands and relatives were independently verified. Targeted exon sequencing using blood (n=1114) or saliva (n=48) samples was done on 72 genes (selected due to associations with increased cancer risk) and rare variants were stratified into classes approximating the International Agency for Research on Cancer (IARC) clinical classification for genetic variation. We did a case-control rare variant burden analysis using 6545 Caucasian controls included from three cohorts (ISKS, 235 controls; LifePool, 2010 controls; and National Heart, Lung, and Blood Institute Exome Sequencing Project [ESP], 4300 controls). Findings The median age at cancer diagnosis in 1162 sarcoma probands was 46 years (IQR 29–58), 170 (15%) of 1162 probands had multiple primary cancers, and 155 (17%) of 911 families with informative pedigrees fitted recognisable cancer syndromes. Using a case-control rare variant burden analysis, 638 (55%) of 1162 sarcoma probands bore an excess of pathogenic germline variants (combined odds ratio [OR] 1·43, 95% CI 1·24–1·64, p TP53, ATM, ATR , and BRCA2 , an unexpected excess of functionally pathogenic variants was seen in ERCC2 . Probands were more likely than controls to have multiple pathogenic variants compared with the combined control cohort group and the LifePool control cohort (OR 2·22, 95% CI 1·57–3·14, p=1·2 × 10 −6 ) and the cumulative burden of multiple variants correlated with earlier age at cancer diagnosis (Mantel-Cox log-rank test for trend, p=0·0032). 66 of 1162 probands carried notifiable variants following expert clinical review (those recognised to be clinically significant to health and about which patients should be advised), whereas 293 (25%) probands carried variants with potential therapeutic significance. Interpretation About half of patients with sarcoma have putatively pathogenic monogenic and polygenic variation in known and novel cancer genes, with implications for risk management and treatment. Funding Rainbows for Kate Foundation, Johanna Sewell Research Foundation, Australian National Health and Medical Research Council, Cancer Australia, Sarcoma UK, National Cancer Institute, Liddy Shriver Sarcoma Initiative.
161 citations
••
TL;DR: External beam radiotherapy is effective in the management of bone metastases for both local and more widespread pain and in spinal canal compression and pathological fracture.
155 citations
••
Medical University of Vienna1, Leiden University Medical Center2, Aarhus University Hospital3, Institut Gustave Roussy4, Tata Memorial Hospital5, University Medical Center Utrecht6, Mount Vernon Hospital7, Post Graduate Institute of Medical Education and Research8, University of Maryland, Baltimore9
TL;DR: A planning aim of ⩽65 Gy EQD2 (EBRT+brachytherapy dose) to the recto-vaginal reference point is proposed to decrease the risk of stenosis.
154 citations
••
TL;DR: Depth is the most significant predictor of cervical node metastasis in early squamous carcinomas of the oral cavity, hence patients with a tumour depth of more than or equal to 5 mm are at an increased risk of harbouring nodes metastasis, hence should be taken up for elective node dissection.
Abstract: Aims Cervical node metastasis is the single most important prognostic factor in head and neck squamous carcinomas. Taking a homogenous patient population, applying stringent selection criteria, and standard pathological evaluation methods, this retrospective study aims to establish histological predictors of subclinical cervical node metastasis in early ( T1–T2/N0 ) squamous carcinomas of the oral cavity, thereby identifying a subset of patients who are at an increased risk for cervical node metastasis. Methods Forty-eight previously untreated patients with clinically T1 or T2, and N0, squamous carcinomas of the oral cavity who were treated with primary excision of the tumour and elective neck node dissection were selected. Various histological factors including T size, gross and microscopic tumour depth and thickness, grade of differentiation, pattern of invasion, inflammatory response, perineural and lymphovascular invasion were studied. The statistical significance of various parameters as predictors of subclinical node metastasis was determined using logistic regression analysis. Results Of all the parameters studied, microscopic tumour depth and thickness were the only significant factors ( P value = 0.026 and 0.046, respectively) which correlated with cervical node metastasis, on univariate analysis. Tumour depth emerged as a single most significant predictor on multivariate analysis. Majority of patients with node metastasis had a tumour depth of more than or equal to 5 mm. Conclusion Depth is the most significant predictor of cervical node metastasis in early squamous carcinomas of the oral cavity. Patients with a tumour depth of more than or equal to 5 mm are at an increased risk of harbouring node metastasis, hence should be taken up for elective node dissection.
154 citations
••
Memorial Sloan Kettering Cancer Center1, Technion – Israel Institute of Technology2, Chang Gung University3, Tata Memorial Hospital4, Royal Prince Alfred Hospital5, University of São Paulo6, University of Cologne7, Tel Aviv Sourasky Medical Center8, Rabin Medical Center9, University of Brescia10, University of Auckland11, Southern Illinois University Carbondale12
TL;DR: This multi-institutional study validates the reliability and applicability of LND as a predictor of outcomes in oral cavity squamous cell carcinoma and can potentially assist in identifying patients with poor outcomes and therefore for whom more aggressive adjuvant treatment is needed.
Abstract: Lymph node density in oral cavity cancer: results of the International Consortium for Outcomes Research
153 citations
Authors
Showing all 3213 results
Name | H-index | Papers | Citations |
---|---|---|---|
Al B. Benson | 113 | 578 | 48364 |
Keitaro Matsuo | 97 | 818 | 37349 |
Ashish K. Jha | 87 | 503 | 30020 |
Noopur Raje | 82 | 506 | 27878 |
Muthupandian Ashokkumar | 76 | 511 | 20771 |
Snehal G. Patel | 73 | 367 | 16905 |
Rainu Kaushal | 58 | 232 | 16794 |
Ajit S. Puri | 54 | 369 | 9948 |
Jasbir S. Arora | 51 | 351 | 15696 |
Sudeep Sarkar | 48 | 273 | 10087 |
Ian T. Magrath | 47 | 107 | 8084 |
Pankaj Chaturvedi | 45 | 325 | 15871 |
Pradeep Kumar Gupta | 44 | 416 | 7181 |
Shiv K. Gupta | 43 | 150 | 8911 |
Kikkeri N. Naresh | 43 | 245 | 6264 |